ID   IKKE_HUMAN              Reviewed;         716 AA.
AC   Q14164; D3DT78; Q3B754; Q3KR43; Q5JTS6;
DT   20-JUN-2001, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1996, sequence version 1.
DT   15-MAR-2017, entry version 176.
DE   RecName: Full=Inhibitor of nuclear factor kappa-B kinase subunit epsilon;
DE            Short=I-kappa-B kinase epsilon;
DE            Short=IKK-E;
DE            Short=IKK-epsilon;
DE            Short=IkBKE;
DE            EC=2.7.11.10;
DE   AltName: Full=Inducible I kappa-B kinase;
DE            Short=IKK-i;
GN   Name=IKBKE; Synonyms=IKKE, IKKI, KIAA0151;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND MUTAGENESIS OF LYS-38;
RP   GLU-168 AND SER-172.
RX   PubMed=10421793; DOI=10.1093/intimm/11.8.1357;
RA   Shimada T., Kawai T., Takeda K., Matsumoto M., Inoue J., Tatsumi Y.,
RA   Kanamaru A., Akira S.;
RT   "IKK-i, a novel lipopolysaccharide-inducible kinase that is related to
RT   IkappaB kinases.";
RL   Int. Immunol. 11:1357-1362(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Leukocyte;
RX   PubMed=10882136; DOI=10.1016/S1097-2765(00)80445-1;
RA   Peters R.T., Liao S.-M., Maniatis T.;
RT   "IKK epsilon is part of a novel PMA-inducible IkappaB kinase
RT   complex.";
RL   Mol. Cell 5:513-522(2000).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Bone marrow;
RX   PubMed=8590280; DOI=10.1093/dnares/2.4.167;
RA   Nagase T., Seki N., Tanaka A., Ishikawa K., Nomura N.;
RT   "Prediction of the coding sequences of unidentified human genes. IV.
RT   The coding sequences of 40 new genes (KIAA0121-KIAA0160) deduced by
RT   analysis of cDNA clones from human cell line KG-1.";
RL   DNA Res. 2:167-174(1995).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS LYS-128; THR-371;
RP   ASP-515; MET-543; VAL-602 AND LEU-713.
RG   SeattleSNPs variation discovery resource;
RL   Submitted (OCT-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   INTERACTION WITH AZI2.
RX   PubMed=14560022; DOI=10.1128/MCB.23.21.7780-7793.2003;
RA   Fujita F., Taniguchi Y., Kato T., Narita Y., Furuya A., Ogawa T.,
RA   Sakurai H., Joh T., Itoh M., Delhase M., Karin M., Nakanishi M.;
RT   "Identification of NAP1, a regulatory subunit of IkappaB kinase-
RT   related kinases that potentiates NF-kappaB signaling.";
RL   Mol. Cell. Biol. 23:7780-7793(2003).
RN   [9]
RP   INTERACTION WITH TICAM1.
RX   PubMed=14739303; DOI=10.1074/jbc.M311629200;
RA   Han K.J., Su X., Xu L.-G., Bin L.H., Zhang J., Shu H.-B.;
RT   "Mechanisms of the TRIF-induced interferon-stimulated response element
RT   and NF-kappaB activation and apoptosis pathways.";
RL   J. Biol. Chem. 279:15652-15661(2004).
RN   [10]
RP   INTERACTION WITH SIKE1; IRF3; TICAM1 AND DDX58.
RX   PubMed=16281057; DOI=10.1038/sj.emboj.7600863;
RA   Huang J., Liu T., Xu L.-G., Chen D., Zhai Z., Shu H.-B.;
RT   "SIKE is an IKK epsilon/TBK1-associated suppressor of TLR3- and virus-
RT   triggered IRF-3 activation pathways.";
RL   EMBO J. 24:4018-4028(2005).
RN   [11]
RP   INTERACTION WITH MAVS.
RX   PubMed=16177806; DOI=10.1038/nature04193;
RA   Meylan E., Curran J., Hofmann K., Moradpour D., Binder M.,
RA   Bartenschlager R., Tschopp J.;
RT   "Cardif is an adaptor protein in the RIG-I antiviral pathway and is
RT   targeted by hepatitis C virus.";
RL   Nature 437:1167-1172(2005).
RN   [12]
RP   FUNCTION, AND INTERACTION WITH AZI2; TANK AND TBKBP1.
RX   PubMed=17568778; DOI=10.1038/sj.emboj.7601743;
RA   Ryzhakov G., Randow F.;
RT   "SINTBAD, a novel component of innate antiviral immunity, shares a
RT   TBK1-binding domain with NAP1 and TANK.";
RL   EMBO J. 26:3180-3190(2007).
RN   [13]
RP   INTERACTION WITH IFIH1.
RX   PubMed=17600090; DOI=10.1073/pnas.0700544104;
RA   Diao F., Li S., Tian Y., Zhang M., Xu L.G., Zhang Y., Wang R.P.,
RA   Chen D., Zhai Z., Zhong B., Tien P., Shu H.B.;
RT   "Negative regulation of MDA5- but not RIG-I-mediated innate antiviral
RT   signaling by the dihydroxyacetone kinase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:11706-11711(2007).
RN   [14]
RP   FUNCTION IN PHOSPHORYLATION OF DDX3X.
RX   PubMed=18583960; DOI=10.1038/emboj.2008.126;
RA   Soulat D., Burckstummer T., Westermayer S., Goncalves A., Bauch A.,
RA   Stefanovic A., Hantschel O., Bennett K.L., Decker T.,
RA   Superti-Furga G.;
RT   "The DEAD-box helicase DDX3X is a critical component of the TANK-
RT   binding kinase 1-dependent innate immune response.";
RL   EMBO J. 27:2135-2146(2008).
RN   [15]
RP   INTERACTION WITH DDX3X.
RX   PubMed=18636090; DOI=10.1038/emboj.2008.143;
RA   Schroder M., Baran M., Bowie A.G.;
RT   "Viral targeting of DEAD box protein 3 reveals its role in
RT   TBK1/IKKepsilon-mediated IRF activation.";
RL   EMBO J. 27:2147-2157(2008).
RN   [16]
RP   INTERACTION WITH CYLD.
RX   PubMed=18636086; DOI=10.1038/embor.2008.136;
RA   Friedman C.S., O'Donnell M.A., Legarda-Addison D., Ng A.,
RA   Cardenas W.B., Yount J.S., Moran T.M., Basler C.F., Komuro A.,
RA   Horvath C.M., Xavier R., Ting A.T.;
RT   "The tumour suppressor CYLD is a negative regulator of RIG-I-mediated
RT   antiviral response.";
RL   EMBO Rep. 9:930-936(2008).
RN   [17]
RP   FUNCTION IN IRF3 PHOSPHORYLATION, INTERACTION WITH EBOLAVIRUS PROTEIN
RP   VP35, AND AUTOPHOSPHORYLATION.
RX   PubMed=19153231; DOI=10.1128/JVI.01875-08;
RA   Prins K.C., Cardenas W.B., Basler C.F.;
RT   "Ebola virus protein VP35 impairs the function of interferon
RT   regulatory factor-activating kinases IKKepsilon and TBK-1.";
RL   J. Virol. 83:3069-3077(2009).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-664, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [19]
RP   FUNCTION, INTERACTION WITH TOPORS, SUMOYLATION AT LYS-231 BY TOPORS,
RP   DESUMOYLATION BY SENP1, MUTAGENESIS OF LYS-231, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=20188669; DOI=10.1016/j.molcel.2010.01.018;
RA   Renner F., Moreno R., Schmitz M.L.;
RT   "SUMOylation-dependent localization of IKKepsilon in PML nuclear
RT   bodies is essential for protection against DNA-damage-triggered cell
RT   death.";
RL   Mol. Cell 37:503-515(2010).
RN   [20]
RP   INTERACTION WITH DDX3X.
RX   PubMed=20657822; DOI=10.1371/journal.ppat.1000986;
RA   Wang H., Ryu W.S.;
RT   "Hepatitis B virus polymerase blocks pattern recognition receptor
RT   signaling via interaction with DDX3: implications for immune
RT   evasion.";
RL   PLoS Pathog. 6:E1000986-E1000986(2010).
RN   [21]
RP   FUNCTION, AND PHOSPHORYLATION BY IKBKB/IKKB.
RX   PubMed=21138416; DOI=10.1042/BJ20101701;
RA   Clark K., Peggie M., Plater L., Sorcek R.J., Young E.R., Madwed J.B.,
RA   Hough J., McIver E.G., Cohen P.;
RT   "Novel cross-talk within the IKK family controls innate immunity.";
RL   Biochem. J. 434:93-104(2011).
RN   [22]
RP   FUNCTION IN AKT PHOSPHORYLATION, AND SUBCELLULAR LOCATION.
RX   PubMed=21464307; DOI=10.1073/pnas.1016132108;
RA   Xie X., Zhang D., Zhao B., Lu M.K., You M., Condorelli G., Wang C.Y.,
RA   Guan K.L.;
RT   "IkappaB kinase epsilon and TANK-binding kinase 1 activate AKT by
RT   direct phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 108:6474-6479(2011).
RN   [23]
RP   FUNCTION, AND INTERACTION WITH ARENAVIRUS PROTEIN N.
RX   PubMed=22532683; DOI=10.1128/JVI.00187-12;
RA   Pythoud C., Rodrigo W.W., Pasqual G., Rothenberger S.,
RA   Martinez-Sobrido L., de la Torre J.C., Kunz S.;
RT   "Arenavirus nucleoprotein targets interferon regulatory factor-
RT   activating kinase IKKepsilon.";
RL   J. Virol. 86:7728-7738(2012).
RN   [24]
RP   FUNCTION, HOMODIMER, INTERACTION WITH IKBKB; IKBKG AND MYD88,
RP   INDUCTION BY LPS, UBIQUITINATION AT LYS-30 AND LYS-401, AND
RP   MUTAGENESIS OF LYS-30; LYS-401 AND LYS-416.
RX   PubMed=23453969; DOI=10.1016/j.celrep.2013.01.031;
RA   Zhou A.Y., Shen R.R., Kim E., Lock Y.J., Xu M., Chen Z.J., Hahn W.C.;
RT   "IKKepsilon-mediated tumorigenesis requires K63-linked
RT   polyubiquitination by a cIAP1/cIAP2/TRAF2 E3 ubiquitin ligase
RT   complex.";
RL   Cell Rep. 3:724-733(2013).
RN   [25]
RP   FUNCTION IN DDX3X AND IRF3 PHOSPHORYLATION, INTERACTION WITH DDX3X AND
RP   IRF3, AND PHOSPHORYLATION AT SER-172.
RX   PubMed=23478265; DOI=10.1128/MCB.01603-12;
RA   Gu L., Fullam A., Brennan R., Schroder M.;
RT   "Human DEAD box helicase 3 couples IkappaB kinase epsilon to
RT   interferon regulatory factor 3 activation.";
RL   Mol. Cell. Biol. 33:2004-2015(2013).
RN   [26]
RP   INTERACTION WITH TRIM6 AND POLYUBIQUITIN, SUBCELLULAR LOCATION, AND
RP   PHOSPHORYLATION AT THR-501.
RX   PubMed=24882218; DOI=10.1016/j.immuni.2014.04.018;
RA   Rajsbaum R., Versteeg G.A., Schmid S., Maestre A.M.,
RA   Belicha-Villanueva A., Martinez-Romero C., Patel J.R., Morrison J.,
RA   Pisanelli G., Miorin L., Laurent-Rolle M., Moulton H.M., Stein D.A.,
RA   Fernandez-Sesma A., tenOever B.R., Garcia-Sastre A.;
RT   "Unanchored K48-linked polyubiquitin synthesized by the E3-ubiquitin
RT   ligase TRIM6 stimulates the interferon-IKKepsilon kinase-mediated
RT   antiviral response.";
RL   Immunity 40:880-895(2014).
RN   [27]
RP   VARIANTS [LARGE SCALE ANALYSIS] THR-371; MET-483; VAL-602; GLU-660 AND
RP   LEU-713.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Serine/threonine kinase that plays an essential role in
CC       regulating inflammatory responses to viral infection, through the
CC       activation of the type I IFN, NF-kappa-B and STAT signaling. Also
CC       involved in TNFA and inflammatory cytokines, like Interleukin-1,
CC       signaling. Following activation of viral RNA sensors, such as RIG-
CC       I-like receptors, associates with DDX3X and phosphorylates
CC       interferon regulatory factors (IRFs), IRF3 and IRF7, as well as
CC       DDX3X. This activity allows subsequent homodimerization and
CC       nuclear translocation of the IRF3 leading to transcriptional
CC       activation of pro-inflammatory and antiviral genes including IFNB.
CC       In order to establish such an antiviral state, IKBKE forms several
CC       different complexes whose composition depends on the type of cell
CC       and cellular stimuli. Thus, several scaffolding molecules
CC       including IPS1/MAVS, TANK, AZI2/NAP1 or TBKBP1/SINTBAD can be
CC       recruited to the IKBKE-containing-complexes. Activated by
CC       polyubiquitination in response to TNFA and interleukin-1,
CC       regulates the NF-kappa-B signaling pathway through, at least, the
CC       phosphorylation of CYLD. Phosphorylates inhibitors of NF-kappa-B
CC       thus leading to the dissociation of the inhibitor/NF-kappa-B
CC       complex and ultimately the degradation of the inhibitor. In
CC       addition, is also required for the induction of a subset of ISGs
CC       which displays antiviral activity, may be through the
CC       phosphorylation of STAT1 at 'Ser-708'. Phosphorylation of STAT1 at
CC       'Ser-708' seems also to promote the assembly and DNA binding of
CC       ISGF3 (STAT1:STAT2:IRF9) complexes compared to GAF (STAT1:STAT1)
CC       complexes, in this way regulating the balance between type I and
CC       type II IFN responses. Protects cells against DNA damage-induced
CC       cell death. Also plays an important role in energy balance
CC       regulation by sustaining a state of chronic, low-grade
CC       inflammation in obesity, wich leads to a negative impact on
CC       insulin sensitivity. Phosphorylates AKT1.
CC       {ECO:0000269|PubMed:17568778, ECO:0000269|PubMed:18583960,
CC       ECO:0000269|PubMed:19153231, ECO:0000269|PubMed:20188669,
CC       ECO:0000269|PubMed:21138416, ECO:0000269|PubMed:21464307,
CC       ECO:0000269|PubMed:22532683, ECO:0000269|PubMed:23453969,
CC       ECO:0000269|PubMed:23478265}.
CC   -!- CATALYTIC ACTIVITY: ATP + [I-kappa-B protein] = ADP + [I-kappa-B
CC       phosphoprotein].
CC   -!- SUBUNIT: Homodimer. Interacts with MAVS/IPS1. Interacts with the
CC       adapter proteins AZI2/NAP1, TANK and TBKBP1/SINTBAD. Interacts
CC       with SIKE1. Interacts with TICAM1/TRIF, IRF3 and DDX58/RIG-I;
CC       interactions are disrupted by the interaction between IKBKE and
CC       SIKE1. Interacts with TOPORS; induced by DNA damage. Interacts
CC       with CYLD. Interacts (when polyubiquitinated) with IKBKB, IKBKG
CC       and MYD88. Interacts with IFIH1 (PubMed:17600090). Interacts with
CC       DDX3X; the interaction is found to be induced upon virus
CC       infection. Interacts (via Protein kinase domain) with arenavirus
CC       protein N; the interaction inhibits IKBKE kinase function.
CC       Interacts with Ebola virus protein VP35; the interaction leads to
CC       inhibition of cellular antiviral response by blocking necessary
CC       interactions between the IKBKE and MAVS/IPS as well as its
CC       substrates IRF3 and IRF7. Interacts with TRIM6 (via SPRY box)
CC       (PubMed:24882218). Interacts with unanchored K48-linked
CC       polyubiquitin chains; this leads to IKBKE activation
CC       (PubMed:24882218). {ECO:0000269|PubMed:14560022,
CC       ECO:0000269|PubMed:14739303, ECO:0000269|PubMed:16177806,
CC       ECO:0000269|PubMed:16281057, ECO:0000269|PubMed:17568778,
CC       ECO:0000269|PubMed:17600090, ECO:0000269|PubMed:18636086,
CC       ECO:0000269|PubMed:18636090, ECO:0000269|PubMed:19153231,
CC       ECO:0000269|PubMed:20188669, ECO:0000269|PubMed:20657822,
CC       ECO:0000269|PubMed:22532683, ECO:0000269|PubMed:23453969,
CC       ECO:0000269|PubMed:23478265, ECO:0000269|PubMed:24882218}.
CC   -!- INTERACTION:
CC       K7Y1A2:- (xeno); NbExp=2; IntAct=EBI-307369, EBI-8788634;
CC       P27958:- (xeno); NbExp=2; IntAct=EBI-307369, EBI-6919131;
CC       Q92624:APPBP2; NbExp=4; IntAct=EBI-307369, EBI-743771;
CC       Q16543:CDC37; NbExp=3; IntAct=EBI-307369, EBI-295634;
CC       O00571:DDX3X; NbExp=4; IntAct=EBI-307369, EBI-353779;
CC       P08238:HSP90AB1; NbExp=2; IntAct=EBI-307369, EBI-352572;
CC       Q14653:IRF3; NbExp=2; IntAct=EBI-307369, EBI-2650369;
CC       Q7Z434:MAVS; NbExp=4; IntAct=EBI-307369, EBI-995373;
CC       Q92844:TANK; NbExp=4; IntAct=EBI-307369, EBI-356349;
CC       Q9UHD2:TBK1; NbExp=2; IntAct=EBI-307369, EBI-356402;
CC       A7MCY6:TBKBP1; NbExp=4; IntAct=EBI-307369, EBI-359969;
CC       Q05127:VP35 (xeno); NbExp=3; IntAct=EBI-307369, EBI-6148294;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:24882218}.
CC       Nucleus. Nucleus, PML body {ECO:0000269|PubMed:20188669}.
CC       Note=Targeting to PML nuclear bodies upon DNA damage is TOPORS-
CC       dependent (PubMed:20188669). Located diffusely throughout the
CC       cytoplasm but locates to punctate cytoplasmic bodies when
CC       coexpressed with TRIM6 (PubMed:24882218).
CC       {ECO:0000269|PubMed:20188669, ECO:0000269|PubMed:24882218}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q14164-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q14164-2; Sequence=VSP_044305;
CC   -!- TISSUE SPECIFICITY: Highly expressed in spleen followed by thymus,
CC       peripheral blood leukocytes, pancreas, placenta. Weakly expressed
CC       in lung, kidney, prostate, ovary and colon.
CC   -!- INDUCTION: Induced by lipopolysaccharide (LPS) and TNFA.
CC       {ECO:0000269|PubMed:23453969}.
CC   -!- PTM: Autophosphorylated and phosphorylated by IKBKB/IKKB.
CC       Phosphorylation at Ser-172 is enhanced by the interaction with
CC       DDX3X. Phosphorylated at Thr-501 upon IFN activation.
CC       {ECO:0000269|PubMed:21138416, ECO:0000269|PubMed:23478265}.
CC   -!- PTM: Sumoylation by TOPORS upon DNA damage is required for
CC       protection of cells against DNA damage-induced cell death.
CC       Desumoylated by SENP1. {ECO:0000269|PubMed:20188669}.
CC   -!- PTM: 'Lys-63'-linked polyubiquitinated at Lys-30 and Lys-401 by
CC       TRAF2:BIRC2 and TRAF2:BIRC3 complexes. Ubiquitination is induced
CC       by LPS, TNFA and interleukin-1 and required for full kinase
CC       activity and KF-kappa-B pathway activation.
CC       {ECO:0000269|PubMed:23453969}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thr
CC       protein kinase family. I-kappa-B kinase subfamily.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAA09772.2; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=SeattleSNPs;
CC       URL="http://pga.gs.washington.edu/data/ikbke/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; D63485; BAA09772.2; ALT_INIT; mRNA.
DR   EMBL; AB016590; BAA85155.1; -; mRNA.
DR   EMBL; AF241789; AAF45307.1; -; mRNA.
DR   EMBL; DQ667176; ABG25921.1; -; Genomic_DNA.
DR   EMBL; AL354681; CAI15250.1; -; Genomic_DNA.
DR   EMBL; CH471100; EAW93549.1; -; Genomic_DNA.
DR   EMBL; BC105923; AAI05924.1; -; mRNA.
DR   EMBL; BC105924; AAI05925.1; -; mRNA.
DR   EMBL; BC107812; AAI07813.1; -; mRNA.
DR   CCDS; CCDS30996.1; -. [Q14164-1]
DR   CCDS; CCDS53464.1; -. [Q14164-2]
DR   RefSeq; NP_001180250.1; NM_001193321.1. [Q14164-2]
DR   RefSeq; NP_001180251.1; NM_001193322.1.
DR   RefSeq; NP_054721.1; NM_014002.3. [Q14164-1]
DR   RefSeq; XP_005273413.1; XM_005273356.2. [Q14164-1]
DR   UniGene; Hs.321045; -.
DR   ProteinModelPortal; Q14164; -.
DR   SMR; Q14164; -.
DR   BioGrid; 115000; 70.
DR   DIP; DIP-27530N; -.
DR   IntAct; Q14164; 40.
DR   MINT; MINT-1132084; -.
DR   STRING; 9606.ENSP00000356087; -.
DR   BindingDB; Q14164; -.
DR   ChEMBL; CHEMBL3529; -.
DR   GuidetoPHARMACOLOGY; 2040; -.
DR   iPTMnet; Q14164; -.
DR   PhosphoSitePlus; Q14164; -.
DR   BioMuta; IKBKE; -.
DR   DMDM; 14548079; -.
DR   EPD; Q14164; -.
DR   MaxQB; Q14164; -.
DR   PaxDb; Q14164; -.
DR   PeptideAtlas; Q14164; -.
DR   PRIDE; Q14164; -.
DR   DNASU; 9641; -.
DR   Ensembl; ENST00000581977; ENSP00000464030; ENSG00000263528. [Q14164-1]
DR   Ensembl; ENST00000584998; ENSP00000462396; ENSG00000263528. [Q14164-2]
DR   GeneID; 9641; -.
DR   KEGG; hsa:9641; -.
DR   UCSC; uc001hdz.3; human. [Q14164-1]
DR   CTD; 9641; -.
DR   DisGeNET; 9641; -.
DR   GeneCards; IKBKE; -.
DR   H-InvDB; HIX0116011; -.
DR   HGNC; HGNC:14552; IKBKE.
DR   HPA; CAB025983; -.
DR   HPA; HPA015788; -.
DR   MIM; 605048; gene.
DR   neXtProt; NX_Q14164; -.
DR   OpenTargets; ENSG00000263528; -.
DR   PharmGKB; PA134962294; -.
DR   eggNOG; KOG4250; Eukaryota.
DR   eggNOG; ENOG410XRMU; LUCA.
DR   GeneTree; ENSGT00820000127009; -.
DR   HOGENOM; HOG000220867; -.
DR   HOVERGEN; HBG008494; -.
DR   InParanoid; Q14164; -.
DR   KO; K07211; -.
DR   OMA; CCLDKMY; -.
DR   OrthoDB; EOG091G0354; -.
DR   PhylomeDB; Q14164; -.
DR   TreeFam; TF324269; -.
DR   BRENDA; 2.7.11.10; 2681.
DR   Reactome; R-HSA-918233; TRAF3-dependent IRF activation pathway.
DR   Reactome; R-HSA-933541; TRAF6 mediated IRF7 activation.
DR   Reactome; R-HSA-936440; Negative regulators of RIG-I/MDA5 signaling.
DR   Reactome; R-HSA-936964; Activation of IRF3/IRF7 mediated by TBK1/IKK epsilon.
DR   SABIO-RK; Q14164; -.
DR   SignaLink; Q14164; -.
DR   SIGNOR; Q14164; -.
DR   ChiTaRS; IKBKE; human.
DR   GeneWiki; IKBKE; -.
DR   GenomeRNAi; 9641; -.
DR   PRO; PR:Q14164; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Bgee; ENSG00000143466; -.
DR   CleanEx; HS_IKBKE; -.
DR   ExpressionAtlas; Q14164; baseline and differential.
DR   Genevisible; Q14164; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0010008; C:endosome membrane; TAS:Reactome.
DR   GO; GO:0031966; C:mitochondrial membrane; IMP:AgBase.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0016605; C:PML body; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0008384; F:IkappaB kinase activity; IEA:UniProtKB-EC.
DR   GO; GO:0036435; F:K48-linked polyubiquitin binding; IMP:UniProtKB.
DR   GO; GO:0004704; F:NF-kappaB-inducing kinase activity; IDA:UniProtKB.
DR   GO; GO:0004672; F:protein kinase activity; TAS:Reactome.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:UniProtKB.
DR   GO; GO:0098586; P:cellular response to virus; IEA:Ensembl.
DR   GO; GO:0006955; P:immune response; NAS:UniProtKB.
DR   GO; GO:0045087; P:innate immune response; IBA:GO_Central.
DR   GO; GO:0008630; P:intrinsic apoptotic signaling pathway in response to DNA damage; IMP:UniProtKB.
DR   GO; GO:0032480; P:negative regulation of type I interferon production; TAS:Reactome.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IBA:GO_Central.
DR   GO; GO:0043123; P:positive regulation of I-kappaB kinase/NF-kappaB signaling; IEP:UniProtKB.
DR   GO; GO:0010884; P:positive regulation of lipid storage; ISS:BHF-UCL.
DR   GO; GO:0051260; P:protein homooligomerization; IDA:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0035456; P:response to interferon-beta; IMP:UniProtKB.
DR   GO; GO:0034340; P:response to type I interferon; IEA:Ensembl.
DR   GO; GO:0035666; P:TRIF-dependent toll-like receptor signaling pathway; TAS:Reactome.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; ATP-binding; Complete proteome; Cytoplasm;
KW   DNA damage; Isopeptide bond; Kinase; Nucleotide-binding; Nucleus;
KW   Phosphoprotein; Polymorphism; Reference proteome;
KW   Serine/threonine-protein kinase; Transferase; Ubl conjugation.
FT   CHAIN         1    716       Inhibitor of nuclear factor kappa-B
FT                                kinase subunit epsilon.
FT                                /FTId=PRO_0000086017.
FT   DOMAIN        9    315       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND      15     23       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   REGION      383    647       Interaction with DDX3X.
FT   REGION      436    457       Leucine-zipper.
FT   ACT_SITE    135    135       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   BINDING      38     38       ATP. {ECO:0000305}.
FT   MOD_RES     172    172       Phosphoserine; by autocatalysis and IKKB.
FT                                {ECO:0000269|PubMed:23478265}.
FT   MOD_RES     501    501       Phosphothreonine.
FT                                {ECO:0000269|PubMed:24882218}.
FT   MOD_RES     664    664       Phosphoserine.
FT                                {ECO:0000244|PubMed:19369195}.
FT   CROSSLNK     30     30       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000269|PubMed:23453969}.
FT   CROSSLNK    231    231       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO1).
FT                                {ECO:0000269|PubMed:20188669}.
FT   CROSSLNK    401    401       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000269|PubMed:23453969}.
FT   VAR_SEQ       1     85       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_044305.
FT   VARIANT     128    128       E -> K (in dbSNP:rs41296028).
FT                                {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_038816.
FT   VARIANT     371    371       A -> T (in dbSNP:rs17021877).
FT                                {ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|Ref.4}.
FT                                /FTId=VAR_038817.
FT   VARIANT     483    483       T -> M (in dbSNP:rs52817862).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040571.
FT   VARIANT     515    515       E -> D (in dbSNP:rs41299015).
FT                                {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_038818.
FT   VARIANT     543    543       I -> M (in dbSNP:rs41299037).
FT                                {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_038819.
FT   VARIANT     602    602       A -> V (in dbSNP:rs12059562).
FT                                {ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|Ref.4}.
FT                                /FTId=VAR_038820.
FT   VARIANT     660    660       G -> E (in dbSNP:rs55822317).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040572.
FT   VARIANT     713    713       P -> L (in dbSNP:rs3748022).
FT                                {ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|Ref.4}.
FT                                /FTId=VAR_019989.
FT   MUTAGEN      30     30       K->A: Loss of ubiquitination and
FT                                decreased kinase activity. No effect on
FT                                homodimerization.
FT                                {ECO:0000269|PubMed:23453969}.
FT   MUTAGEN      30     30       K->R: Loss of ubiquitination and
FT                                decreased kinase activity. Decreases
FT                                interaction with IKBKB, IKBKG and MYD88.
FT                                No effect on homodimerization.
FT                                {ECO:0000269|PubMed:23453969}.
FT   MUTAGEN      38     38       K->A: Loss of kinase activity and loss of
FT                                nuclear import.
FT                                {ECO:0000269|PubMed:10421793}.
FT   MUTAGEN     168    168       E->A: Slight decrease of kinase activity.
FT                                {ECO:0000269|PubMed:10421793}.
FT   MUTAGEN     172    172       S->A: Loss of autophosphorylation and of
FT                                kinase activity.
FT                                {ECO:0000269|PubMed:10421793}.
FT   MUTAGEN     172    172       S->E: Decrease in kinase activity.
FT                                {ECO:0000269|PubMed:10421793}.
FT   MUTAGEN     231    231       K->R: Loss of sumoylation and loss of
FT                                targeting to nuclear bodies.
FT                                {ECO:0000269|PubMed:20188669}.
FT   MUTAGEN     401    401       K->A: Loss of ubiquitination and
FT                                decreased kinase activity. No effect on
FT                                homodimerization.
FT                                {ECO:0000269|PubMed:23453969}.
FT   MUTAGEN     401    401       K->R: Loss of ubiquitination and
FT                                decreased kinase activity. Decreases
FT                                interaction with IKBKB, IKBKG and MYD88.
FT                                No effect on homodimerization.
FT                                {ECO:0000269|PubMed:23453969}.
FT   MUTAGEN     416    416       K->A: No effect on ubiquitination.
FT                                {ECO:0000269|PubMed:23453969}.
FT   MUTAGEN     416    416       K->R: No effect on ubiquitination.
FT                                {ECO:0000269|PubMed:23453969}.
FT   CONFLICT    187    187       R -> Q (in Ref. 7; AAI05925).
FT                                {ECO:0000305}.
SQ   SEQUENCE   716 AA;  80462 MW;  3E5FBE5840734D81 CRC64;
     MQSTANYLWH TDDLLGQGAT ASVYKARNKK SGELVAVKVF NTTSYLRPRE VQVREFEVLR
     KLNHQNIVKL FAVEETGGSR QKVLVMEYCS SGSLLSVLES PENAFGLPED EFLVVLRCVV
     AGMNHLRENG IVHRDIKPGN IMRLVGEEGQ SIYKLTDFGA ARELDDDEKF VSVYGTEEYL
     HPDMYERAVL RKPQQKAFGV TVDLWSIGVT LYHAATGSLP FIPFGGPRRN KEIMYRITTE
     KPAGAIAGAQ RRENGPLEWS YTLPITCQLS LGLQSQLVPI LANILEVEQA KCWGFDQFFA
     ETSDILQRVV VHVFSLSQAV LHHIYIHAHN TIAIFQEAVH KQTSVAPRHQ EYLFEGHLCV
     LEPSVSAQHI AHTTASSPLT LFSTAIPKGL AFRDPALDVP KFVPKVDLQA DYNTAKGVLG
     AGYQALRLAR ALLDGQELMF RGLHWVMEVL QATCRRTLEV ARTSLLYLSS SLGTERFSSV
     AGTPEIQELK AAAELRSRLR TLAEVLSRCS QNITETQESL SSLNRELVKS RDQVHEDRSI
     QQIQCCLDKM NFIYKQFKKS RMRPGLGYNE EQIHKLDKVN FSHLAKRLLQ VFQEECVQKY
     QASLVTHGKR MRVVHETRNH LRLVGCSVAA CNTEAQGVQE SLSKLLEELS HQLLQDRAKG
     AQASPPPIAP YPSPTRKDLL LHMQELCEGM KLLASDLLDN NRIIERLNRV PAPPDV
//
